Advertisement

Neuroblastoma in Neonates

  • Matteo Carella
  • Riccardo Masetti
  • Claudio Antonellini
  • Beatrice Randi
  • Andrea PessionEmail author
  • Mario Lima
Chapter

Abstract

In neonatal period, tumours, although very rare, represent an important cause of morbidity and mortality. The prevalence of neoplasms, within the first month after birth, occurs once in every 12,500–27,500 live births, and malignant tumours develop in approximately 40–50% of them. Diagnosis often occur during prenatal screening or during follow-up for a known cancer predisposition syndrome; in fact the presence of congenital anomalies, multifocal or bilateral diseases and cancer in close relatives is suggestive for an underlying cancer predisposition syndrome, and genetic counselling and testing should be considered to investigate these possibilities.

References

  1. 1.
    Chandrasekaran A. Neonatal solid tumors. Pediatrics and neonatology; 2017.Google Scholar
  2. 2.
    Orbach D, Sarnacki S, Brisse HJ, et al. Neonatal cancer. Lancet Oncol. 2013;14:e609–20.CrossRefGoogle Scholar
  3. 3.
    Moore SW, Satge D, Sasco AJ, Zimmermann A, Plaschkes J. The epidemiology of neonatal tumours. Report of an international working group. Pediatr Surg Int. 2003;19:509–19.CrossRefGoogle Scholar
  4. 4.
    Alfaar AS, Hassan WM, Bakry MS, Qaddoumi I. Neonates with cancer and causes of death; lessons from 615 cases in the SEER databases. Cancer Med. 2017;6:1817–26.CrossRefGoogle Scholar
  5. 5.
    Fisher JP, Tweddle DA. Neonatal neuroblastoma. Semin Fetal Neonatal Med. 2012;17:207–15.CrossRefGoogle Scholar
  6. 6.
    Muller-Schulte E, Kurlemann G, Harder A. Tobacco, alcohol and illicit drugs during pregnancy and risk of neuroblastoma: systematic review. Arch Dis Child Fetal Neonatal Ed. 2018;103(5):F467–73.CrossRefGoogle Scholar
  7. 7.
    Cook MN, Olshan AF, Guess HA, et al. Maternal medication use and neuroblastoma in offspring. Am J Epidemiol. 2004;159:721–31.CrossRefGoogle Scholar
  8. 8.
    Heck JE, Park AS, Qiu J, Cockburn M, Ritz B. An exploratory study of ambient air toxics exposure in pregnancy and the risk of neuroblastoma in offspring. Environ Res. 2013;127:1–6.CrossRefGoogle Scholar
  9. 9.
    French AE, Grant R, Weitzman S, et al. Folic acid food fortification is associated with a decline in neuroblastoma. Clin Pharmacol Ther. 2003;74:288–94.CrossRefGoogle Scholar
  10. 10.
    Tolbert VP, Coggins GE, Maris JM. Genetic susceptibility to neuroblastoma. Curr Opin Genet Dev. 2017;42:81–90.CrossRefGoogle Scholar
  11. 11.
    Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008;8:11–23.CrossRefGoogle Scholar
  12. 12.
    Mossé YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008;455:930–5.CrossRefGoogle Scholar
  13. 13.
    Trochet D, Bourdeaut F, Janoueix-Lerosey I, et al. Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Am J Hum Genet. 2004;74:761–4.CrossRefGoogle Scholar
  14. 14.
    Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003;3:203–16.CrossRefGoogle Scholar
  15. 15.
    Newman EA, Nuchtern JG. Recent biologic and genetic advances in neuroblastoma: implications for diagnostic, risk stratification, and treatment strategies. Semin Pediatr Surg. 2016;25:257–64.CrossRefGoogle Scholar
  16. 16.
    Attiyeh EF, London WB, Mosse YP, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med. 2005;353:2243–53.CrossRefGoogle Scholar
  17. 17.
    Caron H, van Sluis P, de Kraker J, et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med. 1996;334:225–30.CrossRefGoogle Scholar
  18. 18.
    Bown N, Cotterill S, Lastowska M, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med. 1999;340:1954–61.CrossRefGoogle Scholar
  19. 19.
    Shimada H, Ambros IM. Pathology of peripheral neuroblastic tumors. In: NKV C, Cohn SL, editors. Neuroblastoma. Berlin, Heidelberg: Springer; 2005. p. 87–95.CrossRefGoogle Scholar
  20. 20.
    Moppett J, Haddadin I, Foot ABM. Neonatal neuroblastoma. Arch Dis Child Fetal Neonatal Ed. 1999;81:F134–F7.CrossRefGoogle Scholar
  21. 21.
    Matthay KK, Blaes F, Hero B, et al. Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in genoa, Italy, 2004. Cancer Lett. 2005;228:275–82.CrossRefGoogle Scholar
  22. 22.
    Kaplan SJ, Holbrook CT, McDaniel HG, Buntain WL, Crist WM. Vasoactive intestinal peptide secreting tumors of childhood. Am J Dis Child. 1980;134:21–4.PubMedGoogle Scholar
  23. 23.
    Brisse HJ, McCarville MB, Granata C, et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology. 2011;261:243–57.CrossRefGoogle Scholar
  24. 24.
    Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466–77.CrossRefGoogle Scholar
  25. 25.
    Monclair T, Brodeur GM, Ambros PF, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2009;27:298–303.CrossRefGoogle Scholar
  26. 26.
    Davidoff AM. Neuroblastoma. Semin Pediatr Surg. 2012;21:2–14.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Matteo Carella
    • 1
  • Riccardo Masetti
    • 1
  • Claudio Antonellini
    • 2
  • Beatrice Randi
    • 2
  • Andrea Pession
    • 1
    Email author
  • Mario Lima
    • 2
  1. 1.Department of Pediatric Hematology OncologySant’Orsola-Malpighi University HospitalBolognaItaly
  2. 2.Department of Pediatric SurgerySant’Orsola-Malpighi University HospitalBolognaItaly

Personalised recommendations